Fasenra Injection: Benralizumab (30mg)

Fasenra injection is a prescription medication used to treat moderate-to-severe allergic asthma in adults and children aged 12 years or older. It contains benralizumab, a unique monoclonal antibody that targets and inhibits the activity of interleukin-4 receptor alpha (IL-4Rα), a protein crucial for immune response in allergic conditions.

Fasenra injection provides rapid and sustained relief by:
* Reducing inflammation associated with asthma symptoms.
* Inhibiting eosinophil recruitment, which plays a significant role in allergic reactions.
* Minimizing the release of inflammatory mediators.

The dosage of Fasenra is administered as a subcutaneous injection every four weeks. It is important to note that this medication may not be suitable for all patients with asthma. Always consult your doctor or pharmacist before starting any new treatment.

Please remember: This information is for general knowledge only and does not constitute medical advice. Consult your healthcare professional for proper diagnosis, treatment, and guidance regarding Fasenra injection use.